Phaseline

Targets › TCEA1

TCEA1 (Transcription elongation factor A protein 1): drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 4; Infectious disease; next expected readout Dec 2026.

Necessary for efficient RNA polymerase II transcription elongation past template-encoded arresting sites. The arresting sites in DNA have the property of trapping a certain fraction of elongating RNA polymerases that pass through, resulting in locked ternary complexes. (UniProt, P23193)

Open in Phaseline: the race on TCEA1, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Instituto Mexicano del Seguro SocialDTG/3TC
Dolutegravir (integrase strand transfer inhibitor) and lamivudine (nucleoside reverse tran
INTEGRASE, TCEA1Phase 4HIV InfectionDec 2026

Conditions

HIV Infection (1)

Modalities

small molecule (1)

Companies

Instituto Mexicano del Seguro Social (1)

Related targets

INTEGRASE (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.